Table 1.

Square box listings on the 2019 Model List in numbers.

	Number	Examples/comments
Total listings with a square box	108	− 93 unique medicines or fixed-dose combinations − 89 on the core list, 19 on the complementary list
Unrestricted square box*	84	Examples: − simvastatin (representative of statins) − omeprazole (representative of proton pump inhibitors) * some unrestricted listings have reference to acceptable alternatives in the technical report of the meeting where recommendations were made, but these alternatives are not specified in the list.
Qualified square box	24	Examples (specified alternatives): − enoxaparin (nadroparin, dalteparin) − erlotinib (gefitinib, afatinib)
Small molecules	103	Examples (specified alternatives): − bisoprolol (atenolol, metoprolol, carvedilol) − morphine (hydromorphone, oxycodone)
Biological medicines	5	Examples (specified alternatives): − adalimumab [certolizumab pegol, etanercept, golimumab, infliximab (including biosimilars)] − erythropoiesis-stimulating agents [epoetin alfa, beta and theta, darbepoetin alfa, methoxy polyethylene glycol epoetin-beta (including biosimilars)]
Entries without a square box but with named alternatives	14	e.g. cycloserine (terizidone), propofol (thiopental), rituximab (quality-assured biosimilars)